5-氨基乙酰丙酸光动力疗法治疗高级别胶质瘤
本文综述光动力疗法(PDT)的适应证、作用机制、不同光敏剂及免疫调节效应,并汇总临床前与临床研究证据。美国食品药品监督管理局(FDA)已批准PDT用于光化性角化病、巴雷特食管、食管癌、支气管内非小细胞肺癌及脉络膜新生血管等;神经肿瘤领域针对高级别胶质瘤(HGG)的临床试验正在进行。5-氨基乙酰丙酸(5-ALA)是血红素合成途径的中间产物,已获FDA批准用于光化性角化病PDT及胶质瘤手术中荧光引导显示恶性组织。结论认为PDT仍是HGG中有前景的治疗方法,需进一步研究。
要点
- 5-ALA是血红素合成途径中间产物,已获FDA批准用于光化性角化病PDT及胶质瘤术中荧光引导显示恶性组织。
- PDT已获FDA批准用于光化性角化病、巴雷特食管、食管癌、支气管内非小细胞肺癌及脉络膜新生血管。
- 作者认为PDT仍是HGG中有前景的治疗方法,需进一步研究。
核心结论
- 作者认为PDT仍是HGG中有前景的治疗方法,需进一步研究。
- 作者认为5-ALA PDT因5-ALA的细胞内代谢而允许选择性靶向肿瘤。
- 作者认为PDT的免疫调节效应进一步增强其用于HGG治疗的价值,且需要更好的理解。
- 作者认为PDT与HGG辅助治疗的联合将需要在随机对照研究中研究。
研究设计与样本
- 本文为文献综述,检索并分析PDT的适应证、作用机制、不同光敏剂的使用、PDT的免疫调节效应以及用于HGG的临床前和临床研究。
主要发现
- PDT已获FDA批准用于治疗光化性角化病、巴雷特食管、食管癌、支气管内非小细胞肺癌等癌前和恶性疾病,以及脉络膜新生血管。
- 在神经肿瘤领域,针对包括HGG和其他脑肿瘤在内的多种恶性肿瘤的PDT疗效临床试验正在进行中。
- 光敏剂和光敏前体均已用于PDT。
- 5-ALA是血红素合成途径的中间产物,已获FDA批准用于光化性角化病PDT及作为胶质瘤手术中荧光引导显示恶性组织的术中成像剂。
- 新的试验正在进行,以利用5-ALA作为治疗剂对术中切除腔进行PDT以及不可手术HGG的间质PDT。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Photodynamic therapy (PDT) is a two-step treatment involving the administration of a photosensitive agent followed by its activation at a specific light wavelength for targeting of tumor cells. MATERIALS/METHODS: A comprehensive review of the literature was performed to analyze the indications for PDT, mechanisms of action, use of different photosensitizers, the immunomodulatory effects of PDT, and both preclinical and clinical studies for use in high-grade gliomas (HGGs). RESULTS: PDT has been approved by the United States Food and Drug Administration (FDA) for the treatment of premalignant and malignant diseases, such as actinic keratoses, Barrett's esophagus, esophageal cancers, and endobronchial non-small cell lung cancers, as well as for the treatment of choroidal neovascularization. In neuro-oncology, clinical trials are currently underway to demonstrate PDT efficacy against a number of malignancies that include HGGs and other brain tumors. Both photosensitizers and photosensitizing precursors have been used for PDT. 5-aminolevulinic acid (5-ALA), an intermediate in the heme synthesis pathway, is a photosensitizing precursor with FDA approval for PDT of actinic keratosis and as an intraoperative imaging agent for fluorescence-guided visualization of malignant tissue during glioma surgery. New trials are underway to utilize 5-ALA as a therapeutic agent for PDT of the intraoperative resection cavity and interstitial PDT for inoperable HGGs. CONCLUSION: PDT remains a promising therapeutic approach that requires further study in HGGs. Use of 5-ALA PDT permits selective tumor targeting due to the intracellular metabolism of 5-ALA. The immunomodulatory effects of PDT further strengthen its use for treatment of HGGs and requires a better understanding. The combination of PDT with adjuvant therapies for HGGs will need to be studied in randomized, controlled studies.
引用
- Mahmoudi K, Garvey KL, Bouras A, et al. 5-aminolevulinic acid photodynamic therapy for the treatment of high-grade gliomas. J Neurooncol. 2019. PMID: 30659522. doi:10.1007/s11060-019-03103-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。